Assignee profile:

ENGENEIC MOLECULAR DELIVERY PTY LTD

City:

SYDNEY

Country:

Australia

Published Applications:

36

Last publication date:

2023-03-16

Patent Grants:

34

Last grant date:

2025-09-16

Top Inventors for applications by ENGENEIC MOLECULAR DELIVERY PTY LTD

These are the the leading inventors for applications assigned to ENGENEIC MOLECULAR DELIVERY PTY LTD:

Recent patent applications by ENGENEIC MOLECULAR DELIVERY PTY LTD

ENGENEIC MOLECULAR DELIVERY PTY LTD based in SYDNEY, AU has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2023-03-16 ✅ Patent 12,414,968 granted on 2025-09-16
US20230079745A1
Human necessities

COMPOSITIONS COMPRISING BACTERIALLY DERIVED MINICELLS AND METHODS OF USING THE SAME

#2 | 2023-02-09 ✅ Patent 12,551,550 granted on 2026-02-17
US20230041309A1
Human necessities

COMPOSITIONS AND VACCINES FOR TREATING AND/OR PREVENTING CORONAVIRUS VARIANT INFECTIONS AND METHODS OF USING THE SAME

#3 | 2022-06-30
US20220202950A1
Human necessities

COMPOSITIONS COMPRISING BACTERIALLY DERIVED INTACT MINICELLS FOR THERANOSTIC APPLICATIONS

#4 | 2022-04-14 ✅ Patent 12,357,687 granted on 2025-07-15
US20220111038A1
Human necessities

COMPOSITIONS AND VACCINES FOR TREATING AND/OR PREVENTING VIRAL INFECTIONS, AND METHODS OF USING THE SAME

#5 | 2022-04-07 ✅ Patent 12,337,033 granted on 2025-06-24
US20220105177A1
Human necessities

ENCAPSULATED GLYCOLIPID ANTIGENS FOR TREATMENT OF NEOPLASTIC DISEASES

#6 | 2020-02-20 ✅ Patent 11,504,402 granted on 2022-11-22
US20200054689A1
Human necessities

Compositions comprising bacterially derived minicells and methods of using the same

#7 | 2019-07-18 ✅ Patent 11,052,157 granted on 2021-07-06
US20190216946A1
Human necessities

Enhanced loading of intact, bacterially derived vesicles with small molecule compounds

#8 | 2019-03-28 ✅ Patent 10,383,827 granted on 2019-08-20
US20190091160A1
Human necessities

Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells

#9 | 2018-12-27 ✅ Patent 10,583,200 granted on 2020-03-10
US20180369416A1
Human necessities

Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells

#10 | 2018-09-06 ✅ Patent 11,357,860 granted on 2022-06-14
US20180250413A1
Human necessities

Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells

#11 | 2018-05-17 ✅ Patent 10,799,461 granted on 2020-10-13
US20180133163A1
Human necessities

Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells

#12 | 2018-04-12 ✅ Patent 11,485,976 granted on 2022-11-01
US20180100159A1
Chemistry; metallurgy

Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same

#13 | 2018-02-15 ✅ Patent 10,994,014 granted on 2021-05-04
US20180043027A1
Human necessities

Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors

#14 | 2018-02-01 ✅ Patent 10,426,736 granted on 2019-10-01
US20180028456A1
Human necessities

Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells

#15 | 2017-11-16 ✅ Patent 10,500,277 granted on 2019-12-10
US20170326235A1
Human necessities

Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma

#16 | 2017-09-14 ✅ Patent 10,441,546 granted on 2019-10-15
US20170258734A1
Human necessities

Bacterially derived intact minicells that encompass plasmid free DNA and methods of using the same

#17 | 2016-04-28 ✅ Patent 9,730,897 granted on 2017-08-15
US20160113883A1
Human necessities

Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells

#18 | 2016-04-07 ✅ Patent 10,328,159 granted on 2019-06-25
US20160095941A1
Human necessities

Enhanced loading of intact, bacterially derived vesicles with small molecule compounds

#19 | 2016-02-25 ✅ Patent 10,098,847 granted on 2018-10-16
US20160051687A1
Human necessities

Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells

#20 | 2015-12-03 ✅ Patent 9,987,377 granted on 2018-06-05
US20150343092A1
Human necessities

Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells

#21 | 2015-04-09 ✅ Patent 9,731,011 granted on 2017-08-15
US20150098897A1
Human necessities

Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma

#22 | 2014-10-23 ✅ Patent 9,242,007 granted on 2016-01-26
US20140315976A1
Human necessities

Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells

#23 | 2014-08-07 ✅ Patent 9,066,982 granted on 2015-06-30
US20140221459A1
Human necessities

Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells

#24 | 2014-08-07 ✅ Patent 9,867,785 granted on 2018-01-16
US20140220116A1
Human necessities

Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells

#25 | 2014-06-05 ✅ Patent 11,147,883 granted on 2021-10-19
US20140155343A1
Human necessities

Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells

#26 | 2013-10-03 ✅ Patent 8,956,864 granted on 2015-02-17
US20130261170A1
Chemistry; metallurgy

Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells

#27 | 2013-09-12 ✅ Patent 10,076,545 granted on 2018-09-18
US20130236422A1
Human necessities

Pharmaceutically compatible method for purifying intact bacterial minicells

#28 | 2013-07-11 ✅ Patent 9,844,598 granted on 2017-12-19
US20130177499A1
Human necessities

Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors

#29 | 2011-11-10 ✅ Patent 8,591,862 granted on 2013-11-26
US20110275585A1
Human necessities

Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells

#30 | 2011-05-12 ✅ Patent 8,669,101 granted on 2014-03-11
US20110111041A1
Human necessities

Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells

#31 | 2008-12-04 ✅ Patent 8,735,566 granted on 2014-05-27
US20080299084A1
Human necessities

Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells

#32 | 2008-08-07
US20080188436A1
Chemistry; metallurgy

Intact Minicells as Vectors for DNA Transfer and Gene Therapy In Vitro and In Vivo

#33 | 2008-02-28 ✅ Patent 8,772,013 granted on 2014-07-08
US20080051469A1
Human necessities

Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells

#34 | 2008-02-14 ✅ Patent 9,878,043 granted on 2018-01-30
US20080038296A1
Human necessities

Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells

#35 | 2007-12-27 ✅ Patent 8,691,963 granted on 2014-04-08
US20070298056A1
Human necessities

Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells

#36 | 2007-10-11 ✅ Patent 9,169,495 granted on 2015-10-27
US20070237744A1
Human necessities

Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells

Also check out EnGeneIC Molecular Delivery Pty. Ltd.'s (Sydney, Australia) applicant profile with 20 patent applications submitted.

AssigneeID:

67122 ⎘